Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Blogs » Compliance Mentor » Pharmaceutical Company Pleads Guilty to Misbranding Oncology Drugs

    Compliance Mentor
    Compliance Mentor RSS FeedRSS

    compliance-mentor-static-reliasmedia

    Free Monthly News from the Award Winning Publisher of:

    • Hospital Access Management
    • Hospital Case Management
    • Hospital Employee Health
    • Hospital Infection Control
    • Hospital Peer Review
    • Healthcare Risk Management
    • Case Management Advisor
    • IRB Advisor
    • Medical Ethics Advisor
    • Same-Day Surgery

     

    Pharmaceutical Company Pleads Guilty to Misbranding Oncology Drugs

    December 19, 2017
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share
    By Robert B. Vogel, MD, JD

    Robert B. Vogel, MD, JD
    Retinal Ophthalmologist at Piedmont Eye Center, Lynchburg VA;
    Attorney, Overbey Hawkins & Wright, PLLS, Lynchburg, VA;
    Adjunct Professor, Humanities and Bioethics, Liberty University School of Medicine, Lynchburg, VA.

    Executives of AmerisourceBergen Specialty Group (ABSG), a wholly-owned subsidiary of AmerisourceBergen Corporation (ABC), pled guilty in September 2017 to illegally distributing misbranded drugs.

    The criminal charges stemmed from ABSG’s behavior between 2001 and 2014. Two of its subsidiaries, Medical Initiatives Inc. (MII) and Oncology Supplies Company, were accused of selling adulterated products. It was revealed that MII was preparing prefilled syringes of oncology care drugs by removing FDA-approved drug product from the glass vials that contained excess drug and repackaging it into plastic syringes that were sold separately. In addition, MII suspected of preparing these plastic syringes in an unclean environment, creating what MII employees noted as particulate matter in the drug product. The exact chemical nature of the foreign matter was not identified in the DOJ announcement.

    The investigation also revealed that, in preparation of “single use” vials, MII technicians breached the vials multiple times, thereby increasing the risk of contamination. To avoid detection, ABSG did not register MII as a repackager or manufacturer with the FDA, as they were required to do. ABSG claimed that MII was merely a pharmacy, dispensing drugs with prescriptions only.

    At the time of the guilty plea, the total payout to the Department of Justice (DOJ) was thought to be $260 million. But, in a recent filing with the United States Securities and Exchange Commission (SEC), ABC revealed that an additional $625 million will be paid to the government to settle civil allegations brought under the False Claims Act (FCA). The final terms of the agreement are being negotiated and the settlement has not yet been officially announced. The company is required to announce how much money it put in reserve for the settlement — first estimated to be $575 million, and now $625 million.

    As part of its agreement with the DOJ, ABSG signed a compliance and ethics agreement promising to increase oversight and accountability of the individuals involved.
     


    Product Spotlight - Blue

    Hospital Case Management

    Searching for strategies and insights to keep your hospital at its best? Hospital Case Management is your inside look at how your peers have navigated the development, implementation, and adaptation of case management programs. Each month, earn CE/CCM while preparing your facility for the rigors of inspection and stay in touch with the latest regulatory developments in case management.

    Learn More - Orange



    Sponsorship Ad - orange

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Compliance Mentor

    View PDF
    Compliance Mentor - December 2017
    December 1, 2017

    Table Of Contents

    Pharmaceutical Company Pleads Guilty to Misbranding Oncology Drugs

    GAO Recommends CMS Realign Its Antifraud Efforts

    Los Angeles Ambulance Company, Dialysis Center Employee Plead Guilty to Medicare Fraud

    San Diego Nursing Homes Pay to Resolve Kickback and Fraud Allegations

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing